Teplizumab

2023 JDRF Children's Congress Delegates Urge Lawmakers to Support Type 1 Diabetes Research and Access to Affordable Insulin

Retrieved on: 
Tuesday, July 11, 2023
JDRF, Music, Insulin, Life, Capitol Hill, SDP, Pancreas, National Institute of Diabetes and Digestive and Kidney Diseases, Research, Bangladesh Technical Education Board, Congress, United States Senate Committee on Appropriations, Rock & Roll Hall of Fame Covers EP, Kidney, Rock, National Diabetes Education Program, Hearing, Republican, Teplizumab, United Kingdom, Digestive, Disease, Pharmaceutical industry, T1D, Diabetes

WASHINGTON, July 11, 2023 /PRNewswire/ -- Today, JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, urged members of the Senate Appropriations Committee to renew the Special Diabetes Program (SDP) and support policies to ensure insulin is available at an affordable and predictable price. Opened by U.S. Senator Patty Murray (D-WA) and led by U.S. Senators Susan Collins (R-ME) and Jeanne Shaheen (D-NH), the hearing took place during the 2023 JDRF Children's Congress, a biennial event that brings over 160 kids and teens living with T1D face-to-face with lawmakers and top decision-makers. The youth delegates traveled to Washington, D.C. from across the country and JDRF's international affiliates in the United Kingdom, Australia, the Netherlands, and Canada.

Key Points: 
  • The youth delegates traveled to Washington, D.C. from across the country and JDRF's international affiliates in the United Kingdom, Australia, the Netherlands, and Canada.
  • The SDP has accelerated the pace of T1D research through a long-term investment of funding at the National Institutes of Health.
  • We can all agree that there should be research to improve the lives of those with diabetes.
  • Following the hearing, the 2023 JDRF Children's Congress delegates continued their advocacy by meeting with lawmakers in their Capitol Hill offices.

Less than half of endocrinologists are impressed with Tzield's ability to delay T1D (MARKETVUE® REPORT)

Retrieved on: 
Tuesday, July 11, 2023
Insulin, CD3, Pancreas, American Association of Clinical Endocrinologists, Patient, Physician, Risk, Immune system, Mab, REACH, Sanofi, FDA, Disease, Pharmaceutical industry, T1D, Teplizumab

NEWTON, Mass., July 11, 2023 /PRNewswire/ -- Type 1 Diabetes (T1D) is a life-long autoimmune disease where the immune system destroys the insulin-producing islet cells in the pancreas until they no longer produce insulin. To date, insulin replacement therapy has been the backbone of T1D treatment but has a significant treatment burden on patients. Recently, clinical development appears to be shifting towards therapies that could delay the need for insulin and preserve beta cell function.

Key Points: 
  • However, less than half of U.S. clinicians are impressed with the drug's ability to delay T1D onset, according to findings from REACH Market Research .
  • To date, insulin replacement therapy has been the backbone of T1D treatment but has a significant treatment burden on patients.
  • Recently, clinical development appears to be shifting towards therapies that could delay the need for insulin and preserve beta cell function.
  • Endocrinologist, U.S.: "What are the potential benefits of a drug like teplizumab in a person who has stage 2 diabetes?

American Diabetes Association Releases Updates to the 2023 Standards of Care in Diabetes on the Use of Teplizumab in Delaying the Onset of Type 1 Diabetes

Retrieved on: 
Sunday, June 25, 2023
Teplizumab, Medicine, Endocrinology, PPC, Public, Food and Drug Administration, Clinical trial, Classification, Incidence, Pharmacist, Delay, Physician, Section 3, Practitioner, American Diabetes Association, Immune system, MM, Webcast, Diagnosis, FDA, ADA, Epidemiology, Mental health, Abridgement, Food, Section 2, Autoantibody, Disease, Pharmaceutical industry, Medical device, Dietary supplement, MD, Diabetes

ARLINGTON, Va., June 25, 2023 /PRNewswire/ -- Today, the American Diabetes Association® (ADA) published updates to the Standards of Care in Diabetes—2023 (Standards of Care) on the use of teplizumab in delaying the onset of type 1 diabetes.

Key Points: 
  • ARLINGTON, Va., June 25, 2023 /PRNewswire/ -- Today, the American Diabetes Association® (ADA) published updates to the Standards of Care in Diabetes—2023 (Standards of Care) on the use of teplizumab in delaying the onset of type 1 diabetes.
  • Teplizumab is a monoclonal antibody that targets the immune system and has been shown to delay the onset of type 1 diabetes in high-risk individuals.
  • Individuals testing positive for autoantibodies may meet criteria for intervention with teplizumab in order to delay development of diabetes.
  • The Standards of Care in Diabetes—2023 is freely accessible online and is published as a supplement to the January 2023 issue of Diabetes Care® .

Stars Unite on Capitol Hill to Fight Type 1 Diabetes With JDRF

Retrieved on: 
Thursday, June 22, 2023
ESPN, JDRF, NFL, Insulin, International, Senior, 2020 BBC Sports Personality of the Year Award, SDP, Pancreas, Hope, Marriott Marquis, Research, Ketoacidosis, Bangladesh Technical Education Board, Congress, Super Bowl, Sport, Teplizumab, Washington Marriott Marquis, Family, Disease, Entertainment, Pharmaceutical industry, Music, T1D

WASHINGTON, June 22, 2023 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, is thrilled to announce the 2023 JDRF Children's Congress, a three-day Washington D.C event that will bring children living with T1D face-to-face with lawmakers and top decision-makers. Youth delegates from across the country, as well as JDRF's five international affiliates, will be joined by celebrity advocates to call on congress to renew the Special Diabetes Program (SDP) and advocate for policies to ensure insulin is available at an affordable and predictable price.

Key Points: 
  • The SDP has accelerated the pace of T1D research through a long-term investment of funding at the National Institutes of Health.
  • "The Special Diabetes Program has supported critical research that has moved us closer than ever to new treatments for type 1 diabetes and its complications and ultimately cures," said Aaron Kowalski, Ph.D., JDRF CEO.
  • JDRF is particularly grateful to our celebrity advocates for adding their voices to this fight.
  • Their influence and personal experiences are invaluable in raising awareness about type 1 diabetes and the critical need to further research."

JDRF Presents Inaugural Mary Tyler Moore Awards to Members of Congress Leading the Fight Against Type 1 Diabetes

Retrieved on: 
Wednesday, March 22, 2023
JDRF, International Board, Insulin, Senate, Diabetes, T1D, Woman, Research, Bangladesh Technical Education Board, Government, Organization, Congress, M.D, Senator Collins, Nature, Risk, Diana DeGette, Teplizumab, Family, Disease, Film industry, Pharmaceutical industry

WASHINGTON, March 22, 2023 /PRNewswire/ -- Today, JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, presented the inaugural Mary Tyler Moore Awards to three women leaders in Congress who have been instrumental in the fight against T1D. U.S. Senators Susan Collins (R-ME) and Jeanne Shaheen (D-NH), co-chairs of the Senate Diabetes Caucus, were honored alongside Representative Diane DeGette (D-CO), co-chair of the Congressional Diabetes Caucus, for their longstanding support of the T1D community. The ceremony, held during JDRF's annual Government Day, honored the legacy of screen icon Mary Tyler Moore, who was diagnosed with T1D at the age of 33. As international chairman of JDRF from 1984 to 2017, Moore used her influence to bring government, scientists and people living with diabetes together to further T1D advocacy and innovation.

Key Points: 
  • WASHINGTON, March 22, 2023 /PRNewswire/ -- Today, JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, presented the inaugural Mary Tyler Moore Awards to three women leaders in Congress who have been instrumental in the fight against T1D.
  • The ceremony, held during JDRF's annual Government Day, honored the legacy of screen icon Mary Tyler Moore, who was diagnosed with T1D at the age of 33.
  • "When most of the world thinks of Mary Tyler Moore, they immediately picture Mary from the 'Mary Tyler Moore Show'.
  • Senators Collins and Shaheen shared remarks with the audience after accepting the Mary Tyler Moore Awards.

Enable Biosciences Announces Relaunch of Website for Early Detection of Type 1 Diabetes

Retrieved on: 
Tuesday, March 21, 2023
Carolyn Bertozzi, JDRF, Teplizumab, T1D, Research, MD, SAN, Immune system, Autoimmune disease, Sanofi, Health, Autoantibody, Disease, Pharmaceutical industry, Vaccine

SOUTH SAN FRANCISCO, Calif., March 21, 2023 /PRNewswire/ -- Enable Biosciences, a biotechnology company dedicated to developing innovative diagnostics, announced the relaunch of its website, type1testing.enablebiosciences.com , which offers an at-home testing kit for the early detection of type 1 diabetes.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 21, 2023 /PRNewswire/ -- Enable Biosciences, a biotechnology company dedicated to developing innovative diagnostics, announced the relaunch of its website, type1testing.enablebiosciences.com , which offers an at-home testing kit for the early detection of type 1 diabetes.
  • Type 1 diabetes is an autoimmune disease affecting over 1.6 million people in the United States.
  • The relaunch of the site coincides with the approval of a new therapy for type 1 diabetes.
  • The Enable Biosciences website is now live and accepting orders for the early detection testing kit.

JDRF and its affiliates celebrate Teplizumab approval

Retrieved on: 
Tuesday, November 22, 2022
Blood, Teplizumab, Heart, Insulin, Diagnosis, National Diabetes Education Program, Kidney, Health Canada, Degenerative disease, Biomarker, CDN, Pancreas, Disease, Diet, US, JDRF, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Volunteering, Death, NIH, Research, Clinical trial, Eye, FDA, Pharmaceutical industry, Medical device, Dietary supplement, T1D

By delaying the onset of T1D, teplizumab will allow those at high risk of developing the disease to postpone the disease burden and reduce the risks of eye, kidney, nerve and heart disease--complications frequently associated with T1D. Teplizumab’s approval can mean additional years without the burden of blood glucose monitoring and insulin administration. It also gives families time to prepare for a future diagnosis.

Key Points: 
  • Teplizumab is the first therapy available to delay the onset of clinical T1D in people at-risk of developing the disease.
  • Teplizumab can change the course and slow the development of T1D.
  • Teplizumabs approval can mean additional years without the burden of blood glucose monitoring and insulin administration.
  • November is National Diabetes Awareness Month, so the timing of this approval is incredible, said Dave Prowten, President and CEO of JDRF Canada.

MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022
Macrogen, Conjugation, Company, ADC, Exercise, Telephone, Teplizumab, Therapy, Food, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Microdeletion syndrome, GLOBE, Prescription Drug User Fee Act, Anti-CD3 monoclonal antibody, FDA, B7, MCRPC, D, Webcast, Conference, NSCLC, BLA, Acute myeloid leukemia, Half-life, CD123, Large-cell lung carcinoma, Cytokine release syndrome, Research, CEO, Conference call, Clinical trial, Gilead Sciences, PDUFA, ID, NASDAQ, Investor relations, Mab, Melanoma, Patient, Program, Pharmaceutical industry, Vaccine, T1D, Incyte

ET

Key Points: 
  • ET
    ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September30, 2022.
  • Revenue for the quarter ended September30, 2022 included MARGENZA net sales of $4.4 million, compared to $3.6million for the quarter ended September30, 2021.
  • R&D Expenses: Research and development expenses were $48.2 million for the quarter ended September30, 2022, compared to $49.8 million for the quarter ended September30, 2021.
  • SG&A Expenses: Selling, general and administrative expenses were $15.4 million for the quarter ended September30, 2022, compared to $17.2 million for the quarter ended September30, 2021.

Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes

Retrieved on: 
Thursday, October 6, 2022
SAN, AMF, Risk, Medicine, SEC, Form 20-F, Commercialization, Science, SNY, Regulation of tobacco by the U.S. Food and Drug Administration, NASDAQ, U.S. FDA, Research, Annual report, Private Securities Litigation Reform Act, R, Autoantibody, Food, Pharmacovigilance, Marketing, Safety, Social responsibility, Intellectual property, Insulin, Forward-looking statement, Death, FDA, COVID-19, Pancreas, Regulation, Pharmaceutical industry, Medical device, Risk management, T1D, Teplizumab, Sanofi

If approved by the U.S. Food and Drug Administration (FDA), teplizumab would be the first-ever disease-modifying therapy in T1D.

Key Points: 
  • If approved by the U.S. Food and Drug Administration (FDA), teplizumab would be the first-ever disease-modifying therapy in T1D.
  • If approved, Sanofi US will leverage our existing world-class capabilities in diabetes care to enhance efforts in both patient and healthcare provider access.
  • We are prepared to tap into all of our internal expertise to support the successful launch of this innovative therapy."
  • Dependent on a positive decision from the FDA, Provention Bio will contract Sanofi US customer-facing field teams.

MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022
Telephone, ASCO, CEO, GLOBE, Neoplasm, Cancer, Patient, Enoblituzumab, Food, Prostate cancer, Investor relations, American Society of Clinical Oncology, Annual general meeting, Half-life, Conference call, GMP, Safety, B7, BLA, Webcast, Conference, ID, PSA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ADC, Teplizumab, PD-1, European Medicines Agency, CD123, AML, Johns Hopkins University, Large-cell lung carcinoma, MCRPC, D, SCCHN, Â, B7-H3, Head, Melanoma, FDA, Acute myeloid leukemia, PDUFA, Mab, Microdeletion syndrome, Macrogen, Society, Workforce, Cytokine release syndrome, Review, Neck, Company, Therapy, Prescription Drug User Fee Act, NASDAQ, Research, Anti-CD3 monoclonal antibody, Pharmaceutical industry, Fine chemical, Vaccine, Incyte

ROCKVILLE, Md., Aug. 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June30, 2022.

Key Points: 
  • ROCKVILLE, Md., Aug. 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June30, 2022.
  • We made important progress in the second quarter, during which we completed enrollment in a Phase 1/2 dose expansion study of lorigerlimab, a PD-1 CTLA-4 DART molecule.
  • Recent progress and anticipated events in 2022 related to MacroGenics investigational product candidates in clinical development are highlighted below.
  • Revenue for the quarter ended June30, 2022 included MARGENZA net sales of $4.7 million, compared to $3.2million for the quarter ended June30, 2021.